Search Results

There are 20126 results for: content related to: Central Versus Peripheral Antagonism of Cannabinoid CB1 Receptor in Obesity: Effects of LH-21, a Peripherally Acting Neutral Cannabinoid Receptor Antagonist, in Zucker Rats

  1. You have free access to this content
    The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism – or inverse agonism – as potential obesity treatment and other therapeutic use

    Journal of Clinical Pharmacy and Therapeutics

    Volume 32, Issue 3, June 2007, Pages: 209–231, S. Xie, M. A. Furjanic, J. J. Ferrara, N. R. McAndrew, E. L. Ardino, A. Ngondara, Y. Bernstein, K. J. Thomas, E. Kim, J. M. Walker, S. Nagar, S. J. Ward and R. B. Raffa

    Version of Record online : 2 MAY 2007, DOI: 10.1111/j.1365-2710.2007.00817.x

  2. Cannabinoid type 1 receptor antagonists for smoking cessation

    Intervention Review

    The Cochrane Library

    Kate Cahill and Michael H Ussher

    Published Online : 16 MAR 2011, DOI: 10.1002/14651858.CD005353.pub4

  3. You have free access to this content
    Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats

    British Journal of Pharmacology

    Volume 163, Issue 7, August 2011, Pages: 1550–1562, L Fattore, MS Spano, V Melis, P Fadda and W Fratta

    Version of Record online : 12 JUL 2011, DOI: 10.1111/j.1476-5381.2011.01459.x

  4. You have free access to this content
    Rimonabant Redux and Strategies to Improve the Future Outlook of CB1 Receptor Neutral-Antagonist/Inverse-Agonist Therapies

    Obesity

    Volume 19, Issue 7, July 2011, Pages: 1325–1334, Sara Jane Ward and Robert B. Raffa

    Version of Record online : 10 SEP 2012, DOI: 10.1038/oby.2011.69

  5. Rimonabant for overweight or obesity

    Intervention Review

    The Cochrane Library

    Cintia Curioni and Charles André

    Published Online : 18 OCT 2006, DOI: 10.1002/14651858.CD006162.pub2

  6. You have free access to this content
    The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction

    Addiction Biology

    Volume 13, Issue 2, June 2008, Pages: 160–187, José Antonio López-Moreno, Gustavo González-Cuevas, Guillermo Moreno and Miguel Navarro

    Version of Record online : 16 APR 2008, DOI: 10.1111/j.1369-1600.2008.00105.x

  7. CB1 receptor antagonists: new discoveries leading to new perspectives

    Acta Physiologica

    Volume 205, Issue 1, May 2012, Pages: 41–60, E. Kirilly, X. Gonda and G. Bagdy

    Version of Record online : 11 FEB 2012, DOI: 10.1111/j.1748-1716.2011.02402.x

  8. You have free access to this content
    Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation

    British Journal of Pharmacology

    Volume 160, Issue 3, June 2010, Pages: 615–626, R Makwana, A Molleman and ME Parsons

    Version of Record online : 3 MAR 2010, DOI: 10.1111/j.1476-5381.2010.00717.x

  9. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies

    Addiction Biology

    Volume 13, Issue 2, June 2008, Pages: 239–252, Bernard Le Foll, Benoit Forget, Henri-Jean Aubin and Steven R. Goldberg

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1369-1600.2008.00113.x

  10. You have free access to this content
    Effects of Chronic Oral Rimonabant Administration on Energy Budgets of Diet-Induced Obese C57BL/6 Mice

    Obesity

    Volume 20, Issue 5, May 2012, Pages: 954–962, Li-Na Zhang, Yuko Gamo, Rachel Sinclair, Sharon E. Mitchell, David G. Morgan, John C. Clapham and John R. Speakman

    Version of Record online : 10 SEP 2012, DOI: 10.1038/oby.2011.357

  11. You have free access to this content
    Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant

    Journal of Neurochemistry

    Volume 112, Issue 5, March 2010, Pages: 1338–13351, Elena Martín-García, Aurelijus Burokas, Miquel Martín, Fernando Berrendero, Blanca Rubí, Christoph Kiesselbach, Andrea Heyne, Juan Domingo Gispert, Olga Millán and Rafael Maldonado

    Version of Record online : 17 DEC 2009, DOI: 10.1111/j.1471-4159.2009.06549.x

  12. The cannabinoid receptor 1 and its role in influencing peripheral metabolism

    Diabetes, Obesity and Metabolism

    Volume 16, Issue 4, April 2014, Pages: 294–304, L. O'Keefe, A. C. Simcocks, D. H. Hryciw, M. L. Mathai and A. J. McAinch

    Version of Record online : 10 JUL 2013, DOI: 10.1111/dom.12144

  13. You have free access to this content
    The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys

    British Journal of Pharmacology

    Volume 164, Issue 2b, September 2011, Pages: 655–666, Jennifer L Stewart and Lance R McMahon

    Version of Record online : 28 AUG 2011, DOI: 10.1111/j.1476-5381.2011.01388.x

  14. You have free access to this content
    The Effects of Rimonabant on Brown Adipose Tissue in Rat: Implications for Energy Expenditure

    Obesity

    Volume 17, Issue 2, February 2009, Pages: 254–261, Aaron N.A. Verty, Andrew M. Allen and Brian J. Oldfield

    Version of Record online : 6 SEP 2012, DOI: 10.1038/oby.2008.509

  15. The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome

    The Journal of Clinical Pharmacology

    Volume 47, Issue 5, May 2007, Pages: 642–652, Dr Anna I. Kakafika, Dr Dimitri P. Mikhailidis, Dr Asterios Karagiannis and Dr Vasilios G. Athyros

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007299358

  16. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 7, July 2010, Pages: 591–603, L. Zhang, N. J. Lee, A. D. Nguyen, R. F. Enriquez, S. J. Riepler, B. Stehrer, E. Yulyaningsih, S. Lin, Y. C. Shi, P. A. Baldock, H. Herzog and A. Sainsbury

    Version of Record online : 21 DEC 2009, DOI: 10.1111/j.1463-1326.2009.01193.x

  17. You have free access to this content
    CB1-independent mechanisms of Δ9-THCV, AM251 and SR141716 (rimonabant)

    Journal of Clinical Pharmacy and Therapeutics

    Volume 37, Issue 3, June 2012, Pages: 260–265, R. B. Raffa and S. J. Ward

    Version of Record online : 11 JUL 2011, DOI: 10.1111/j.1365-2710.2011.01284.x

  18. You have free access to this content
    Effect of the Cannabinoid Receptor-1 Antagonist Rimonabant on Inflammation in Mice With Diet-Induced Obesity

    Obesity

    Volume 19, Issue 3, March 2011, Pages: 505–513, Qun Wang, Xiaoyuan D. Perrard, Jerry L. Perrard, Amir Mansoori, C. Wayne Smith, Christie M. Ballantyne and Huaizhu Wu

    Version of Record online : 6 SEP 2012, DOI: 10.1038/oby.2010.213

  19. You have free access to this content
    Pharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation

    British Journal of Pharmacology

    Volume 159, Issue 8, April 2010, Pages: 1608–1622, R Makwana, A Molleman and ME Parsons

    Version of Record online : 5 MAR 2010, DOI: 10.1111/j.1476-5381.2009.00592.x

  20. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 2, February 2010, Pages: 158–166, N. Perwitz, J. Wenzel, I. Wagner, J. Büning, M. Drenckhan, K. Zarse, M. Ristow, W. Lilienthal, H. Lehnert and J. Klein

    Version of Record online : 5 NOV 2009, DOI: 10.1111/j.1463-1326.2009.01133.x